Sebastiano Buti

Medical Oncologist at University Hospital of Parma and Researcher at Department of Medicine and Surgery - University of Parma, Italy

[Yüksel Ürün @DrYukselUrun]

KIM-1 in oligometastatic ccRCC.
KIM-1 and ctDNA are independently prognostic.
@DrChoueiri @VincentWenxinXu @PavlosMsaouel @lilli_ash @Clara__Steiner #GU26 @EUplatinum @ASCO @OncoAlert

[Sebastiano Buti @Sebastiano_Buti]

When is immunotherapy too much? The case of favorable-risk metastatic ... https://t.co/VG9ctCAPME

[Yüksel Ürün @DrYukselUrun]

Early EV dose reduction in advanced urothelial cancer ↘️ treatment interruption risk by half, yet survival stayed the same.
@JAMAOnc @OncoAlert @WorldBladderCan @Uromigos
https://t.co/sbC1ZA95EW

[Dana-Farber News @DanaFarberNews]

In a new study published in @CCR_AACR, @DanaFarber researchers found the effects of immunotherapy can last after treatment stops in patients with advanced non-small cell lung cancer. @DFarberThoracic

Read more: https://t.co/GIjAvnNQT7

[Yüksel Ürün @DrYukselUrun]

BREAKING from @NEJM
In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is :
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection.
#Thrombosis #cancer @OncoAlert @Cihan_Ay_MD
DOI: 10.1056/NEJMoa2416112

[Yüksel Ürün @DrYukselUrun]

20 years ago, metastatic melanoma meant death in a year.
Today?
🔸 10-yr Overall Survival: 43% (nivo+ipi)
🔸 10-yr Melanoma-Specific Survival: 52%
This isn’t improvement. It’s a revolution.
Believe in science.
#Melanoma #Immunotherapy #Oncology #Cancer
@NEJM @asco @myESMO @sitcancer @OncoAlert @oncodaily
https://t.co/gW7GEbNpxJ

[Sebastiano Buti @Sebastiano_Buti]

GRANT Score has beeen validated also in patients with resected papillary RCC https://t.co/QsIg9TgGKC

[Yüksel Ürün @DrYukselUrun]

50 years of vaccines = 154 million lives saved!

Since 1974, childhood vaccines have been the biggest driver of infant survival, preventing 40% of infant deaths globally. Immunization isn’t just protection—it’s a lifesaver. #VaccinesWork #PublicHealth
@TheLancet @WHO @CDCgov
@EricTopol @Atul_Gawande
https://t.co/mDjIFYrWVK

[Yüksel Ürün @DrYukselUrun]

💊 7 vs. 14 Days of Antibiotics?
For bloodstream infections, 7 days = 14 days in 90-day mortality! @NEJM
Mortalities:
7 days: 14.5%
14 days: 16.1%
Less is more!!! @oergonul1
https://t.co/ifHmfdOmvL

[Sebastiano Buti @Sebastiano_Buti]

The Italian hospital medical profession is broken too - The Lancet Regional Health – Europe https://t.co/uoouiiZIYI

[Roberto Iacovelli @DrIacovelli]

This morning I have found this on my desk... I am so proud of this achievement! 😁 Thanks 🙏 to all investigators & @EUplatinum for supporting Academic Research in GU cancers.
Stay tuned 🛜 for other news from TIDE-A trial! @Uroweb @urofocus @OncoAlert @oncodaily @GUOncologyNow @OncLive

[Sebastiano Buti @Sebastiano_Buti]

Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney - Clinical Genitourinary Cancer https://t.co/T27JoR8fib

[Giuseppe Banna @gbanna74]

The potential of RBC-based scores to improve prognostic systems in metastatic renal cell carcinoma. Identifying patients with better prognosis and exploring molecular correlates could refine treatment strategies, #mRCC #CancerResearch #Oncology #IUCS @OncoAlert @OncoViews

[OncoDaily @oncodaily]

@gbanna74 @OncoAlert @OncoViews @RebuzziSara @GFornarini @therealmarcodoc @PasRescigno @biostat84 @Uroweb @urologysummit @gu_onc We are delighted to inform you that your post has been successfully published on Oncodaily. Thank you for sharing such valuable content.
https://t.co/YPrajU2IRq

[OncoDaily @oncodaily]

RBC-based scores improving prognostic systems in metastatic RCC - @gbanna74
@OncoViews @RebuzziSara @Sebastiano_Buti

https://t.co/YPrajU2IRq

#Cancer #OncoDaily #Oncology #NHS #CancerCare

[Sebastiano Buti @Sebastiano_Buti]

Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab https://t.co/4FE3xl6bZe

[Karl Semaan, MD, MSc @KarlSemaan]

1/ 🚨 Just in @EUplatinum , our study on first-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma.
Effort co-led with @TalalZarif1, with amazing mentorship from @DrDanielHeng @DrChoueiri

https://t.co/ReHSdoMRWy

@DanaFarber_GU @YaleMed @OncoAlert

[Sebastiano Buti @Sebastiano_Buti]

ITALIAN REGISTRY ON RARE UROLOGICAL TUMORS (MEET-URO-23): THE FIRST ANALYSIS ON COLLECTING DUCT CARCINOMA OF THE KIDNEY - Clinical Genitourinary Cancer https://t.co/T27JoR7HsD

[Sebastiano Buti @Sebastiano_Buti]

Intersecting Blood Cytokines With Cholesterol Parameters to ... : Journal of Immunotherapy https://t.co/kvfrEJk6Ve

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Amazing performance by the stellar @CityofHope_GU team’s junior investigators👉Two back to back @NatureMedicine original research articles from their IIT studies. Congrats @EbrahimiHedyeh @NazliDizman & team and the mega-mentor @montypal Cc @ASCO @OncoAlert @Uromigos @kidneycan